Quick Facts

• Condition/Goal: Reduction of infection risk (febrile neutropenia) following certain types of chemotherapy.
• Condition/Goal: Management of low white blood cell counts in severe chronic neutropenia.
• Condition/Goal: Mobilization of blood cells for collection prior to stem cell transplant procedures.
• Condition/Goal: Support of blood cell recovery after bone marrow transplantation.
• Condition/Goal: Support of survival in individuals exposed to high levels of radiation.

---

Neupogen (filgrastim) is administered to support the body's count of infection-fighting white blood cells, known as neutrophils. The use of this medicine is generally confined to specific therapeutic circumstances that involve a reduction in the normal production of these cells.

Its primary function is to help lower the potential for infection, a circumstance often observed in patients receiving myelosuppressive anti-cancer treatments that are known to decrease neutrophil levels. This process is intended to reduce the duration of low neutrophil counts following chemotherapy or bone marrow transplantation.

Neupogen is also indicated for the long-term management of symptomatic severe chronic neutropenia, a group of conditions involving consistently low neutrophil counts. Additionally, it is used to assist in the mobilization of hematopoietic progenitor cells into the blood for collection and subsequent use in autologous stem cell transplant therapy. In approved circumstances, it is also utilized to contribute to increased survival in patients acutely exposed to myelosuppressive doses of radiation. The objective across all uses is to support the body's natural defense against infection during periods of compromised blood cell production.

Eligibility Map: Who can and cannot use Neupogen 480 — official regulatory information

---

Eligibility Scope

Classification	Rule Summary (Official Labeling)
Populations for whom use is allowed	Adults and children with Severe Chronic Neutropenia (SCN) and those receiving myelosuppressive chemotherapy; patients undergoing bone marrow transplantation or peripheral blood stem cell mobilization; patients acutely exposed to radiation.
Populations for whom use is not recommended	Patients with Myelodysplastic Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in the non-chemotherapy setting; patients receiving simultaneous radiation and chemotherapy.
Populations for whom use is contraindicated	Patients with a known history of serious allergic reactions (hypersensitivity) to Filgrastim, Pegfilgrastim, or proteins derived from E. coli.

---

Age and Condition-Based Eligibility

Classification	Rule Summary (Official Labeling)
Age-related eligibility rules	Use is established in both pediatric and geriatric populations for labeled indications; no major age-related restrictions apply to adults.
Condition-specific eligibility rules	No dose adjustment is required for patients with severe renal or hepatic impairment. Use in patients with a Sickle Cell Disorder is permitted but restricted due to the heightened risk of sickle cell crisis.
Pregnancy and lactation eligibility status	Use during pregnancy is not generally recommended unless the potential benefit justifies the potential risk. It is not known if the drug is excreted in human milk; caution is advised during breastfeeding.

---

Connection to the overall eligibility profile

Official government regulatory documents define eligibility by establishing clear contraindications that prohibit use (such as allergy to E. coli proteins) and restrictions that limit use in specific conditions (like MDS/AML or sickle cell disease). The drug's use is established in a broad range of patients, including pediatric and geriatric age groups, with specific organ function rules indicating no required dose adjustment for severe renal or hepatic impairment.

The official regulatory profile for Neupogen (filgrastim) is primarily defined by required administration timing and pharmacodynamic effects with specific co-administered agents.

Interaction Classification	Documented Entities	Regulatory Statement Focus
Administration Timing Restriction	Cytotoxic Chemotherapy and Bone Marrow Infusion	Prohibits concurrent use during a critical period due to the sensitivity of rapidly dividing myeloid cells.
Pharmacodynamic Interaction	Lithium and Antimetabolites	Notes potential for additive effect on neutrophil release (Lithium) or increased myelosuppression (Antimetabolites).

Official Interaction Statements

The use of filgrastim is subject to strict procedural constraints related to other treatments. Filgrastim must not be administered in the period 24 hours before to 24 hours after the cytotoxic chemotherapy dose, as officially documented by regulatory agencies. This rule is designed to prevent potentiation of the effects of cytotoxic agents on rapidly dividing myeloid cells.

For patients undergoing bone marrow transplantation, the first dose is similarly restricted and must be administered at least 24 hours after the bone marrow infusion.

The pharmacodynamic interaction domain includes substances like Lithium, which the official label notes may lead to additive leukopoietic effects due to its role in promoting neutrophil release. Additionally, co-administration with antimetabolite chemotherapy agents may lead to potentiated myelosuppression.

No pharmacokinetic drug interactions, such as those involving the CYP enzyme system or changes to clearance, are explicitly described in the regulatory prescribing information, and no interactions with food, alcohol, or herbal products are officially documented.

Neupogen (filgrastim) functions as a recombinant agonist of the endogenous human Granulocyte Colony-Stimulating Factor (G-CSF). The biological target is the G-CSF receptor (G-CSF-R), a transmembrane protein primarily expressed on hematopoietic progenitor cells and mature neutrophils within the bone marrow.

Binding of filgrastim to G-CSF-R induces receptor dimerization, which initiates a cascade of intracellular signaling pathways. The primary downstream pathway activated is the JAK/STAT pathway, specifically Janus Kinase (JAK) phosphorylation leading to Signal Transducer and Activator of Transcription (STAT) protein activation. Filgrastim also activates the PI3K/AKT and MAPK/ERK pathways.

These molecular and intracellular pathways collectively modulate gene expression, resulting in enhanced proliferation, differentiation, and survival of neutrophil progenitor cells. The consequence is accelerated neutrophil maturation and subsequent mobilization, promoting the rapid release of a high number of functionally active, mature neutrophils from the bone marrow storage pool into the peripheral circulation.

How to Use Neupogen (Filgrastim): Official Administration Guidelines

Neupogen (filgrastim) is administered via the parenteral route, most commonly by subcutaneous (SC) injection, though intravenous (IV) infusion is also an approved route for high-dose regimens. The administration method is standardized based on the patient's body weight, with dosage measured in micrograms per kilogram (mu g/ kg) daily.

Dosing and Scheduling

The typical starting dosage for patients receiving myelosuppressive chemotherapy is 5 mu g/ kg administered once daily. For support following bone marrow transplantation or for the mobilization of peripheral blood cells, the recommended dose is often higher, at 10 mu g/ kg daily. The drug’s schedule is governed by a strict timing constraint relative to cytotoxic chemotherapy: administration must begin no sooner than 24 hours after the completion of chemotherapy and must not be given within the 24-hour period prior to it.

Course Duration and Preparation

The total duration of use is not fixed but is directly linked to the patient’s Absolute Neutrophil Count (ANC) response. Daily administration continues until the ANC rises above a specified threshold. For intravenous use, the solution must be strictly diluted in 5% glucose solution for preparation. No specific dose adjustments are required for older adults or individuals with severe renal or hepatic impairment.

This protocol ensures a standardized, weight-based approach to administration, with the treatment course dictated by objective laboratory parameters.

Recent Clinical Evidence

Clinical trials involving Neupogen (filgrastim), the active ingredient in Neupogen 480, focus primarily on its approved use for managing neutropenia, a condition characterized by a low count of neutrophils (a type of white blood cell) in the blood. Research examines the use of filgrastim to help stimulate the production and release of neutrophils from the bone marrow.

---

Studies in Chemotherapy-Induced Neutropenia

Research has explored the role of filgrastim in reducing the duration and severity of neutropenia following standard chemotherapy. Trials have investigated whether filgrastim administration is associated with a decrease in the incidence of febrile neutropenia (fever accompanied by neutropenia), a serious complication that often leads to hospitalization and treatment delays.

Primary Outcome Evaluated	Research Focus
Duration of severe neutropenia	Comparing time in days until absolute neutrophil count (ANC) recovery.
Incidence of fever	Evaluating the percentage of patients developing a fever while neutropenic.

Data from clinical studies support the role of filgrastim in accelerating neutrophil recovery. However, the use of filgrastim has not been shown to affect overall survival rates in all clinical settings examined.

---

Other Investigated Uses

Studies have also examined filgrastim in patients undergoing autologous peripheral blood progenitor cell (PBPC) collection. Here, the research focuses on whether filgrastim administration can mobilize sufficient stem cells into the peripheral blood for subsequent collection and transplantation. Findings suggest that filgrastim is effective for this purpose. Additionally, research explores its use in specific populations, such as in patients with severe chronic neutropenia, where trials evaluate whether regular administration is associated with a sustained increase in neutrophil counts and a lower risk of infection.

Common questions about Neupogen 480 (FAQ)

---

Q: How soon after starting Neupogen 480 might someone expect blood count changes?

Studies and official information indicate that the drug's effect begins quickly, with a rise in neutrophil counts typically seen within 1 to 2 days after starting therapy. Clinical trials support that filgrastim works by accelerating the recovery of the Absolute Neutrophil Count (ANC).

---

Q: Can Neupogen 480 cause pain in the bones or joints?

Yes. According to official product information, bone pain (musculoskeletal pain) is reported very frequently in clinical data. Joint pain (arthralgia) is also listed as a commonly reported side effect.

---

Q: Can Neupogen 480 be used alongside common pain relievers?

Official regulatory documents do not provide specific guidance on interactions with common pain relievers. The prescribing information states that drug interactions have not been fully evaluated, but notes that other drugs not specifically studied may be used alongside it.

---

Q: Does alcohol use affect the function of Neupogen 480?

No official regulatory documents explicitly describe interactions with food, alcohol, or herbal products.

---

Q: How do medical professionals monitor the progress of a patient using Neupogen 480?

Monitoring typically involves taking a baseline Complete Blood Count (CBC) with differential, followed by serial CBCs. This testing is performed to check the patient is responding and to identify when the Absolute Neutrophil Count (ANC) meets specific thresholds for stopping treatment.

---

Q: Why is Neupogen 480 sometimes given to healthy donors for stem cell collection?

Filgrastim is approved to mobilize (release) Peripheral Blood Progenitor Cells (PBPCs) from the bone marrow into the peripheral blood. This is done in healthy donors who are preparing to give their stem cells for an allogeneic transplantation procedure.

---

Q: Is Neupogen 480 only used in cancer treatment?

No. While commonly used to support cancer treatment (e.g., following chemotherapy), it is also approved for the long-term treatment of Severe Chronic Neutropenia (SCN) and to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Acute Radiation Syndrome).

---

Q: Are there specific clinical trials that support the use of Neupogen 480 in particular diseases?

Yes. Official clinical studies support its approved use in chemotherapy-induced neutropenia, following bone marrow transplantation, in Severe Chronic Neutropenia (SCN), and for the mobilization of progenitor cells.

---

Q: How is Neupogen 480 different from Neulasta (pegfilgrastim)?

Filgrastim (Neupogen) is a short-acting Granulocyte Colony-Stimulating Factor (G-CSF) that typically requires daily administration. Pegfilgrastim (Neulasta) is a long-acting, pegylated version that often requires a single dose per chemotherapy cycle due to its extended presence in the body. Both are used for similar indications.

---

Q: Does Neupogen 480 affect only the white blood cells?

Filgrastim primarily works to increase the production of neutrophils, a specific type of white blood cell. However, official documents note that the drug's activity can also result in changes to other blood cell types, such as a decrease in platelet counts.

---

Q: Are there any long-term side effects noted in the research for Neupogen 480?

Yes. In patients with Severe Chronic Neutropenia (SCN), long-term administration has been associated with the potential development of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Additionally, decreased bone density has been reported in children receiving long-term treatment for SCN.

---

Q: Is it possible to have an allergic reaction to Neupogen 480?

Yes, serious allergic reactions, including anaphylaxis, have been reported in patients receiving filgrastim. These reactions have sometimes occurred upon initial exposure and usually within 30 minutes of administration.

---

Q: What if a user forgets to use Neupogen 480 for one day?

Official patient information recommends contacting the healthcare provider right away for guidance on the next dose. They can provide advice specific to the patient's individual treatment schedule.

---

Q: Is Neupogen 480 meant to be used for a short time or long term?

The drug is used both short-term (e.g., following chemotherapy) until the white blood cell count recovers, and long-term. For chronic conditions like Severe Chronic Neutropenia (SCN), long-term daily administration is used to maintain an adequate neutrophil count.

---

Q: Is Neupogen 480 used for all types of low white blood cell counts?

No. Filgrastim is a Granulocyte Colony-Stimulating Factor (G-CSF) specifically approved to increase neutrophils, which is only one type of white blood cell. It is not indicated for the primary treatment of low counts in other types of white blood cells.

---

Q: What is the connection between Neupogen 480 and severe chronic neutropenia?

Filgrastim is approved for the long-term treatment of Severe Chronic Neutropenia (SCN). Its purpose in this condition is to maintain an adequate neutrophil count, thereby helping to manage the risk and duration of associated complications, such as fever and infections.

---

Q: What are the general guidelines for using Neupogen 480 in pediatric patients?

The use of filgrastim is established in the pediatric population for approved indications, including Severe Chronic Neutropenia and neutropenia following chemotherapy. The safety and efficacy have not been established in infants younger than 1 month of age.

---

Q: Does Neupogen 480 affect the outcome of chemotherapy?

Clinical studies indicate that filgrastim reduces the incidence and duration of complications, such as febrile neutropenia, which can lead to chemotherapy delays. However, studies have not shown an impact on overall survival in all clinical settings examined.

---

Q: How is the need for Neupogen 480 determined by a doctor?

A doctor determines the need based on the patient’s underlying medical condition (such as receiving myelosuppressive chemotherapy), the expected risk of developing severe neutropenia, and the patient's Absolute Neutrophil Count (ANC).

---

Q: What should a patient do if they accidentally use more Neupogen 480 than prescribed?

Official patient information recommends contacting the healthcare provider or seeking emergency medical help right away.

---

Q: Is it normal to feel tired or weak after using Neupogen 480?

Yes, fatigue is listed as a very common side effect in the product information. Generalized weakness and asthenia (physical weakness or lack of energy) are also listed as common side effects.

---

Q: What organs are described in official documents as being potentially affected by Neupogen 480?

Official regulatory warnings list several organs that may be affected. These include the spleen (splenic rupture), lungs (Acute Respiratory Distress Syndrome), kidneys (glomerulonephritis), and the major blood vessel aorta (aortitis).

---

Q: Is there a generic version of Neupogen 480 available?

Yes, filgrastim is available as biosimilar products, which are approved versions of the reference product Neupogen.

---

Q: Why do some people receive a lower dose than 480 micrograms?

The prescribed dose is typically calculated based on the patient’s body weight ( mu g/kg ), not a fixed amount. Patients with lower body weights, therefore, naturally require and receive doses that are lower than 480 micrograms.

---

Q: How does Neupogen 480 help with infections?

The drug accelerates the production and release of neutrophils, which are crucial white blood cells that fight bacterial and fungal infections. By raising the count of these cells, it is used to manage the risk and incidence of infection associated with severe neutropenia.

---

Q: What kind of follow-up care is typically expected when using Neupogen 480?

Routine follow-up care includes repeated Complete Blood Counts (CBCs) to monitor the patient's neutrophil response. This type of monitoring is standard to evaluate the neutrophil response and determine the appropriate time to discontinue the medication.

---

Q: What happens when a person stops using Neupogen 480?

Upon stopping daily administration, the Absolute Neutrophil Count (ANC) is expected to decline. Regulatory documents note that the ANC can decrease by approximately 50% within the first two days after discontinuation.

---

Q: Does Neupogen 480 cause hair loss or weight changes?

According to the product’s adverse reaction data, hair loss (alopecia or thinning) is listed as a common side effect. Weight loss and loss of appetite are also listed as common side effects reported.

---

Q: Why is the 480 microgram dose fixed, or can it be adjusted?

While 480 micrograms is a fixed concentration and volume available for the product, the actual dose given is typically determined by the patient's body weight. For long-term conditions like Severe Chronic Neutropenia (SCN), the daily dose is individually adjusted based on the patient’s neutrophil count response.

---

Q: What does the term 'dose-dense' mean in relation to Neupogen 480 use?

Dose-dense chemotherapy refers to cancer treatment regimens where cycles are given more frequently than usual. Filgrastim is used to support these regimens by preventing neutropenia-related delays, allowing the full dose-dense schedule to be delivered as planned.

---

Q: What is the process for official regulatory bodies approving Neupogen 480?

The approval process requires the submission of a comprehensive application to agencies like the FDA or EMA. This application must include data from robust non-clinical studies and clinical trials that demonstrate the drug's quality, safety, and effectiveness for the intended uses.

---

Q: Does Neupogen 480 affect the results of other laboratory tests?

Yes, filgrastim can lead to changes in certain lab test results. These transient changes include increases in levels of Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH), and uric acid. It also significantly elevates white blood cell counts, which is the intended effect.

---

Q: What is the difference between chemotherapy-induced neutropenia and other types of neutropenia?

Regulatory documents approve the drug for different types of neutropenia. Chemotherapy-Induced Neutropenia is temporary, caused by cytotoxic drugs, and requires short-term treatment. Severe Chronic Neutropenia (SCN) is a persistent, non-cancer-related deficiency that requires long-term, daily treatment to maintain cell counts.

---

Q: Are there specific studies about the use of Neupogen 480 in patients with HIV?

Governmental health sources note that filgrastim has been used in patients with HIV to manage neutropenia. This neutropenia may be caused by the disease process itself or by certain medications used to treat HIV.

Official Storage, Handling, and Disposal Requirements

Mandatory Storage Conditions

Requirement Type	Official Statement
Storage Temperature	Store in the refrigerator at 2 C to 8 C (36 F to 46 F).
Stability and Integrity	Do not freeze and do not shake the prefilled syringe or vial.
Light Protection	Keep the product in the original carton until the time of use to protect it from light.

Stability and Handling

If the medication is removed from the refrigerator, it may be allowed to reach room temperature (up to 25 C) for a single period of up to 24 hours. Any Neupogen left at room temperature for longer than 24 hours must be discarded. The prefilled syringe or vial is single-use only; any unused portion of medicine must be discarded immediately after the required dose is withdrawn.

Disposal of Used Materials

To dispose of used syringes and needles, place them immediately into an FDA-cleared sharps disposal container. The sharps container, once full, must be disposed of according to local and state regulations; used syringes and needles must not be placed in household trash or recycled. Neupogen must be kept out of the sight and reach of children at all times, including the sharps disposal container.